Inogen | INGN - Selling And Administration Expenses


Inogen reported $43.77M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
AngioDynamics USD 35.99M 14K Feb/2025
AtriCure USD 78.23M 158K Sep/2025
Baxter International USD 708M 10M Sep/2025
Becton, Dickinson and Co. USD 1.39B 27M Dec/2025
Boston Scientific USD 1.83B 93M Dec/2025
Chart Industries USD 136M 9.3M Sep/2025
Cooper Companies USD 419.2M 12M Sep/2025
Dexcom USD 331.4M 3.4M Sep/2025
Edwards Lifesciences USD 602.9M 88.3M Dec/2025
Globus Medical USD 313.6M 9.98M Sep/2025
Inogen USD 43.77M 510K Jun/2024
Insulet USD 315.2M 61.9M Sep/2025
Masimo USD 116.4M 20.5M Sep/2025
Medtronic 2.97B 159M Sep/2025
Orthofix International USD 112.21M 1.1M Sep/2024
Philips EUR 1.31B 127M Dec/2025
ResMed USD 278.4M 19.2M Dec/2025
Steris USD 352.3M 2.6M Dec/2025
Stryker USD 2.14B 150M Dec/2025
Tandem Diabetes Care USD 94.52M 1.47M Sep/2025
Teleflex USD 281.76M 66.68M Sep/2025
X T L Biopharmaceuticals USD 706K 50K Dec/2024
Zimmer Biomet Holdings USD 855.7M 44.3M Dec/2025